In my practice, I regularly see a version of the same patient a man in his early 50s who had the kind of cardiac workup his primary care doctor called reassuring: cholesterol and blood pressure within the traditionally acceptable ranges, no family history of heart disease
This suggests that GHK-Cu and related peptides could be investigated as potential non-addictive research alternatives in the context of pain management, alongside opiate medications and NSAIDs, which are known for their potential side effects, including negative impacts on cardiovascular health
Workflows where convenience matters and the 5:1:1 GHK-Cu-dominant ratio fits the goal
In simpler terms, BPC-157 tells your body to heal faster, more completely, and with less discomfort along the way
The areas attracting the most focused attention include inflammatory bowel disease, where the preclinical evidence base is deepest
PepPal also explains why berberine is not "nature's Ozempic"